drugset / Trial / NCT03160261

Effect of Exenatide on Cortisol Secretion

NCT03160261

Phase 4 Completed 10 enrolled University of Tartu
NaSingle-groupOpen-labelDiagnostic

Summary

The primary aim of the study is to describe the effect of single dose of 10 micrograms (μg) exenatide given subcutaneously (s/c) on cortisol secretion. Secondary outcomes involve ACTH and glucose levels.

Timeline

Start
2017-09-07
Primary completion
2017-12-28
Completion
2017-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 10 ug Subcutaneous

Indications

No indication recorded.